Viaskin Peanut’s Phase 3 comeback plus Palforzia’s exit creates a rare opening—now DBV’s value hinges on FDA approval and flawless launch execution.
Overview
DBV Technologies is a late-stage French biopharma advancing Viaskin, an epicutaneous immunotherapy (EPIT) patch platform aimed at desensitizing children with serious food allergies—initially peanut allergy—to reduce risk from accidental exposure and anaphylaxis. EPIT delivers microgram quantities of allergen to superficial skin layers, targeting Langerhans cells and promoting immune tolerance while limiting systemic exposure compared with oral immunotherapy. As of 2025/early 2026 the company is transitioning from pure clinical-stage toward pre-commercial: it has no product revenue and its operating income is mainly French R&D tax credits (about $5.0M for 9M 2025). The core near-term market is pediatric peanut allergy in ages 1–7, split into toddlers (1–3) and children (4–7), with an estimated ~670,000 U.S. children in this band. DBV’s near-term trajectory is shaped by Phase 3 success (VITESSE) and upcoming BLAs in 2026, funded by a major early-2026 financing event (€166.7M gross from warrant exercises) intended to support regulatory submissions and commercial build toward a potential 2027 launch.